Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 24

1.

Protecting Our Forces: Improving Vaccine Acquisition and Availability in the U.S. Military.

Institute of Medicine (US) Committee on a Strategy for Minimizing the Impact of Naturally Occurring Infectious Diseases of Military Importance: Vaccine Issues in the U.S. Military; Lemon SM, Thaul S, Fisseha S, O'Maonaigh HC, editors.

Washington (DC): National Academies Press (US); 2002.

2.

Giving Full Measure to Countermeasures: Addressing Problems in the DoD Program to Develop Medical Countermeasures Against Biological Warfare Agents.

Institute of Medicine (US) and National Research Council (US) Committee on Accelerating the Research, Development, and Acquisition of Medical Countermeasures Against Biological Warfare Agents; Joellenbeck LM, Durch JS, Benet LZ, editors.

Washington (DC): National Academies Press (US); 2004.

3.

The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from Discovery Through Approval: Workshop Summary.

Institute of Medicine (US) Forum on Medical and Public Health Preparedness for Catastrophic Events, Institute of Medicine (US) Forum on Drug Discovery, Development, and Translation.

Washington (DC): National Academies Press (US); 2010.

4.

Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies: Workshop Summary.

Institute of Medicine (US) Forum on Drug Discovery, Development, and Translation.

Washington (DC): National Academies Press (US); 2009.

5.

Peer-to-Peer Sharing Spurs Scientific Innovation.

Zerhouni EA.

Sci Transl Med. 2009 Dec 2;1(9):9ed2. doi: 10.1126/scitranslmed.3000584. No abstract available.

6.

A call for sharing: adapting pharmaceutical research to new realities.

Munos BH, Chin WW.

Sci Transl Med. 2009 Dec 2;1(9):9cm8. doi: 10.1126/scitranslmed.3000155.

PMID:
20368187
7.

Trends in risks associated with new drug development: success rates for investigational drugs.

DiMasi JA, Feldman L, Seckler A, Wilson A.

Clin Pharmacol Ther. 2010 Mar;87(3):272-7. doi: 10.1038/clpt.2009.295. Epub 2010 Feb 3. Review.

PMID:
20130567
8.

Lessons from 60 years of pharmaceutical innovation.

Munos B.

Nat Rev Drug Discov. 2009 Dec;8(12):959-68. doi: 10.1038/nrd2961. Review.

PMID:
19949401
9.

Intellectual property. Balancing innovation and access: patent challenges tip the scales.

Higgins MJ, Graham SJ.

Science. 2009 Oct 16;326(5951):370-1. doi: 10.1126/science.1176116. No abstract available.

PMID:
19833944
10.

BARDA's budget.

Klotz LC, Pearson A.

Nat Biotechnol. 2009 Aug;27(8):698-9; author reply 699. doi: 10.1038/nbt0809-698. No abstract available.

PMID:
19668170
11.

Drug and vaccine development for infectious diseases: the value of priority review vouchers.

Matheny J, Smith B, Courtney B, Mair M.

Clin Pharmacol Ther. 2009 Jun;85(6):571-2. doi: 10.1038/clpt.2009.53. No abstract available.

PMID:
19451907
12.

Cost/success projections for US biodefense countermeasure development.

Matheny J, Mair M, Smith B.

Nat Biotechnol. 2008 Sep;26(9):981-3. doi: 10.1038/nbt0908-981. No abstract available.

PMID:
18779804
13.

The FDA animal efficacy rule and biodefense.

Gronvall GK, Trent D, Borio L, Brey R, Nagao L; Alliance for Biosecurity..

Nat Biotechnol. 2007 Oct;25(10):1084-7. No abstract available.

PMID:
17921984
14.

Incentives for biodefense countermeasure development.

Matheny J, Mair M, Mulcahy A, Smith BT.

Biosecur Bioterror. 2007 Sep;5(3):228-38.

PMID:
17903091
15.

Office of the Assistant Secretary for Preparedness and Response; HHS Public Health Emergency Medical Countermeasures Enterprise implementation plan for chemical, biological, radiological and nuclear threats. Notice.

Office of the Assistant Secretary for Preparedness and Response, Department of Health and Human Services..

Fed Regist. 2007 Apr 23;72(77):20117-28.

16.

Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness.

Berndt ER, Glennerster R, Kremer MR, Lee J, Levine R, Weizs├Ącker G, Williams H.

Health Econ. 2007 May;16(5):491-511.

PMID:
17013993
17.

Can open-source R&D reinvigorate drug research?

Munos B.

Nat Rev Drug Discov. 2006 Sep;5(9):723-9. Epub 2006 Aug 18. Review.

PMID:
16915233
18.

Applying the concepts of financial options to stimulate vaccine development.

Brogan D, Mossialos E.

Nat Rev Drug Discov. 2006 Aug;5(8):641-7. doi: 10.1038/nrd2035. Epub 2006 Jul 14. Review.

PMID:
16883302
19.

A breakthrough in R&D for neglected diseases: new ways to get the drugs we need.

Moran M.

PLoS Med. 2005 Sep;2(9):e302. Epub 2005 Sep 8. No abstract available. Erratum in: PLoS Med. 2005 Oct;2(10):e376.

20.

Encouraging the development of new vaccines.

Grabowski H.

Health Aff (Millwood). 2005 May-Jun;24(3):697-700.

Supplemental Content

Support Center